(R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid
CAS: 451470-34-1
Ref. 3D-BTA47034
1mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Informação sobre produto
- 3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid
- Gw 427353b
- Solabegron hydrochloride
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-, hydrochloride (1:1)
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-, monohydrochloride
(R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid (Tolterodine tartrate) is a drug that is used to treat various types of urinary incontinence. It acts as an antimuscarinic by binding to the muscarinic receptors in the detrusor muscle and bladder wall, thereby decreasing involuntary contractions. Tolterodine tartrate has shown clinical response rates of up to 80% in patients with overactive bladder. It has been approved for use in adults and children who are at least 6 years old. Clinical trials have shown that this drug can also be used to reduce symptoms of urge incontinence and mixed incontinence. The pharmacological treatment is usually started with a low dose, which is gradually increased until it reaches the desired effect.
Propriedades químicas
Consulta técnica sobre: 3D-BTA47034 (R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.